A robust antibody discovery platform is an important core factor that determines the success of a set of drug modalities. The area of antibody discovery has seen tremendous technological advancement, offering pharma companies a wide range of tools to choose from. At Aurigene, we design our monoclonal antibody discovery programs keeping the therapeutic end point in mind and choose the technology platform accordingly.
Our team has experience in handling several technology platforms including humanized rodents, B-cell cloning, hybridoma, and display libraries. Fit-for-purpose tools and reagent monoclonal antibodies are generated to meet the program needs.
Antigen generation and Immunization strategies
- RNA, membrane and whole cell immunization
- Immunization with conjugate antigens
- Immunization with whole-cell, recombinant cell lines, nano disc and membrane preparations
- Immunization protocols; standard, RImMS and hybrid
- Neonatal strategy for better epitope specificity and less immunogenic epitope
- Display technologies: phage, yeast and mammalian: Under development
- Strong expertise in anti-idiotypic antibody discovery (blockers/non-blockers with single digit nM/pM affinity) to support PK / ADA assays
Hybridoma and B-Cell cloning
- Antigen-specific single B-cell sorting, sequencing / v-gene recovery, sub-cloning / reformatting, expression, screening and monoclonal selection
- Enriched B-cell or target-specific B-cell fusion methodologies
- Highly efficient and optimized fusion (PEG and electrofusion) technologies for generating hybridoma
Screening & evaluation strategies
- Multitier high-throughput screening strategies using flow cytometry, ELISA, and octet
- Analytical SE-HPLC, BIAcore, functional assay and mass spectrometry to support analytics
- Functional assay & fit-for-purpose assay (IHC, Western blotting etc.) for evaluation
Why Aurigene Pharmaceutical Services?
Single B-cell cloning
Humanized rodent platform
Display platforms (Phage/ Yeast)
Hybridoma
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...
Read More
Accelerating Drug Discovery Through Innovative Partnerships
Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....
Read More
Expediting early development through innovative precision capsule filling technology
Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...
Read More
A metal catalyst-free and one-pot synthesis of (3,4- dihydro-2H-benzo[b][1,4]oxazin-2-yl)methanol derivatives in water
2015
A robust and metal catalyst-free method has been developed for the general and green synthesis of racemic (3,4-dihydro-2H-benzo[b][1,4] oxazin-2-yl)methanol derivatives. This simple, mild and practical method involves the reaction of 2-aminophenols with ()-epichlorohydrin in the presence of NaOH in water at room temperature. The reaction features high regioselec...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
A Sensitive and a Simple RP-HPLC Method Development and Verification for the Quantitative Estimation of Cholecalciferolin Tablets
2005
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis [1]. It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization [2]. IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market